Phosphorylated protein and peptide substrates (p-Protein substrates)

Phosphorylated protein and peptide substrates represent a broad category of cellular proteins that have undergone post-translational modification via the addition of a phosphate group to serine, threonine, or tyrosine residues. This modification is governed by the opposing actions of protein kinases (which add phosphate) and protein phosphatases (which remove it), serving as a primary molecular switch for regulating protein activity, localization, and complex formation [1][4]. In a biological context, these substrates are essential for relaying signals from the cell surface to the nucleus, controlling critical processes such as the cell cycle, metabolic flux, and programmed cell death [2]. Dysregulation of the phosphorylation status within this substrate class is a hallmark of many diseases; for example, hyperphosphorylation of Tau protein is linked to Alzheimer's disease, while constitutive phosphorylation of signaling proteins like Akt and ERK drives many forms of cancer [5]. While therapeutic agents rarely target the phosphorylated substrates themselves, they frequently target the enzymes responsible for modulating these states, making the substrates vital biomarkers for monitoring drug efficacy and disease progression [4][6].

Other names

PhosphoproteinsPhosphopeptidesSerine/threonine/tyrosine phosphorylated proteinsPhosphoproteomeProtein phosphatase substrates

Drugs typically do not target the phosphorylated substrates directly; instead, they inhibit protein phosphatases (e.g., PP1, PP2A, PP2B/calcineurin) to prevent the dephosphorylation of these substrates or inhibit protein kinases to prevent their formation [1][2]. Small molecules like cyclosporine and tacrolimus act by inhibiting the phosphatase calcineurin, thereby maintaining the phosphorylated state of substrates like NFAT to achieve immunosuppression [3].